Your browser doesn't support javascript.
loading
An insight into Clostridioides difficile-associated diarrhea in Saudi children: diagnosis and treatment.
Thabit, Abrar K; Aljedaani, Huda J; Alghamdi, Rawan H; Badahdah, Raghad M; Lashkar, Manar O; Alnajjar, Abeer.
Afiliação
  • Thabit AK; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Aljedaani HJ; Department of Pharmaceutical Care, King Khalid Hospital, Ministry of Health, Najran, Saudi Arabia.
  • Alghamdi RH; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Badahdah RM; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Lashkar MO; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Alnajjar A; Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Expert Rev Gastroenterol Hepatol ; 17(8): 805-810, 2023.
Article em En | MEDLINE | ID: mdl-37480286
ABSTRACT

INTRODUCTION:

Clostridioides difficile infection (CDI) is a major cause for antibiotic-associated diarrhea. Specific factors put the pediatrics at risk. International guidelines lists specific recommendations for the diagnosis and treatment of pediatric CDI. The practice of diagnosing and treating pediatric CDI in Saudi Arabia is slightly different from the recommendations of the guidelines. AREAS COVERED This review summarizes pediatric CDI in Saudi Arabia in terms of epidemiology, current diagnostics, and how the practice compares to recommendations of the guidelines, and available treatment options. EXPERT OPINION Although pediatric CDI epidemiology in Saudi Arabia doesn't impose a burden on the healthcare system, it should be noted that not all hospitals follow CDI diagnostic recommendations of international guidelines, which may result in cases underreporting. However, due to the presumed low CDI prevalence, the traditional regimen of oral metronidazole for non-severe CDI remains effective, whereas vancomycin is used for severe cases. While fidaxomicin is approved for pediatrics, its high acquisition cost and low CDI rates make it challenging for hospitals to use it. Overall, pediatrics at risk of CDI recurrence should be evaluated, such as reviewing current antibiotics for potential discontinuation. Future studies evaluating the epidemiology and treatment for CDI in Saudi children are needed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Clostridioides difficile / Infecções por Clostridium Tipo de estudo: Diagnostic_studies / Guideline / Risk_factors_studies Limite: Child / Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Clostridioides difficile / Infecções por Clostridium Tipo de estudo: Diagnostic_studies / Guideline / Risk_factors_studies Limite: Child / Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article